Liquid Biopsy-based Risk Stratification and Intensification of Treatment In EGFR Mutant Advanced NSCLC (L-BRITE)U

Liquid Biopsy-based Risk Stratification and Intensification of Treatment In EGFR Mutant Advanced NSCLC (L-BRITE)U

Saved in:

Bibliographic Details
Main Authors:	H. Baskarane, P. Malik, D. Jain, C. Sh, S. Khurana, A. Kumar, S. Kumar
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	The Journal of Liquid Biopsy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950195423000644
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01)

Genomic Profiling in NSCLC: Insights from Liquid Biopsy
by: C. Ercolani, et al.
Published: (2023-11-01)

Mutational Prognosis of Survival by Liquid Biopsy in Advanced EGFRm NSCLC
by: M. Galvez-Nino, et al.
Published: (2023-11-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives
by: Molly S.C. Li, et al.
Published: (2024-03-01)

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC
by: Jiaxin Liu, et al.
Published: (2024-11-01)

Der Brite als ein diskursiv erzeugter Gegenstand: Bedeutungsvarianten, Synonyme, Hyperonyme und Antonyme der lexikalischen Einheit Brite im Brexit-Diskurs der „Tageszeitung“
by: Agnieszka Gaweł
Published: (2024-12-01)

BLU-945 Monotherapy and Combination With Osimertinib in Previously Treated Patients With Advanced EGFR-Mutant (EGFRm) NSCLC in Phase 1/2 SYMPHONY Study
by: Y. Elamin, et al.
Published: (2023-11-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
by: Álvaro Taus, et al.
Published: (2012-01-01)

Liquid Biopsy Analysis Shows MAGI2 Gene as Potential Negative Prognosis Biomarker in NSCLC Patients
by: P. Mediavilla, et al.
Published: (2023-11-01)

Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy
by: Haolun Ding, et al.
Published: (2025-01-01)

Inhibitory effect of 1,4,5,6-tetrahydroxy-7,8-diprenylxanthone against NSCLC with L858R/T790M/C797S mutant EGFR
by: Jing Wang, et al.
Published: (2024-11-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Clinical Feasibility of NGS Liquid Biopsy Analysis in NSCLC Patients Using Oncomine Precision Assay with Genexus™ Integrated Sequencer
by: S. Buglioni, et al.
Published: (2023-11-01)

Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel, et al.
Published: (2020-03-01)

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
by: Brian J. Thomas, et al.
Published: (2024-11-01)

Circulating Tumor Cells of Non-small Cell Lung Cancer (NSCLC) Patients. A Potential New Liquid Biopsy Biomarker
by: E. Fernández Armúa, et al.
Published: (2023-11-01)

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment
by: Sara Marchisio, et al.
Published: (2024-11-01)

Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma
by: Mojtaba Sadeghi, et al.
Published: (2024-12-01)

Professional care at household: some reflections from Brazil A Dialogue between Jurema Brites and Claudia Fonseca
by: Jurema Brites, et al.
Published: (2014-09-01)

NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers
by: Michela Verzè, et al.
Published: (2024-06-01)

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2024-12-01)

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY
by: Jill Feldman, MA, et al.
Published: (2025-03-01)

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
by: Antonio Rossi, et al.
Published: (2022-12-01)

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC
by: Jacqueline V. Aredo, MD, MS, et al.
Published: (2024-12-01)

Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases
by: Guangchuan Deng, et al.
Published: (2024-12-01)

The first issue of the official journal of the International Society of Liquid Biopsy: The Journal of Liquid Biopsy
by: Umberto Malapelle, et al.
Published: (2023-09-01)

Theranostics aspect of extracellular vesicle in cancer liquid biopsy
by: Shivani Ravipati, et al.
Published: (2024-03-01)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
by: Chee Khoon Lee, PhD, et al.
Published: (2025-02-01)

Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report
by: Yoshihiro Go, et al.
Published: (2024-12-01)

Liquid biopsy - a review
by: WERONIKA RUTKOWSKA-KAWALEC, et al.
Published: (2025-01-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)